IODAX Pharma AG

The >> 3rd dimension of radiopharmaceuticals
>> made in Germany

News

  • Astatine – A new dimension in PSMA therapy.

    IODAX is very pleased to announce in-licensing of the unique PSAt-Ga technology for PSMA-targeting from Theranostic Solutions, Copenhagen, Denmark. 

    The technology uniquely allows for labelling with either [211At]astatine, or [131I]iodine in a metabolically protected position. In addition, [68Ga]gallium labelling is possible, enabling diagnostic use and state of the art mass dose optimisation (JNM 2024, 65 (4) 593-599).

    Astatine is the only known non-metal alpha emitter allowing for covalent bonding to organic molecules. It can be conveniently produced in cyclotrons from inexpensive non-enriched regular bismuth in unlimited amounts. Its favourable half-life of 7,1h and 79 keV emission of its daughter nuclide 211Po allow for convenient direct SPECT imaging using modern CZT SPECT detectors (https://doi.org/10.1007/s00259-024-07017-w)

    The license provides global commercial rights.

Vision

Molecular Radiotherapy (MRT) with Small Molecules – Combining classical oncological pharmacology with radiation physics

Malignant transformation of cells is associated with the expression of tumour-related metabolic abnormalities, successfully targeted by “classical” (non-radioactive, >> Small Molecule) anti-tumour drugs, such as e.g. tyrosin kinase inhibitors (TKIs). The vast majority of such oncological targets is >> inside the cell (“intracellular”).

Conventional radiopharmaceuticals for MRT use >> Macromolecules, such a monoclonal antibodies (MABs) or peptides, to target tumour cells. Due to their size and polarity (“linkers”, “chelators” and “radiometals”), such agents can target >> only extracellular tumour targets on the cell surface (2-dimensional).

In contrast, >> Small Molecules, covalenly labelled with >> Halogens (fluorine, iodine or astatine) can directly enter the cell through the membrane, allowing to administer a >> Duplicate Anti-Tumour Effect, consisting of a pharmacological PLUS a radiation treatment in the entire cell volume (3-dimensional).

For Investors

From Licensed Assets to Market-Ready Drugs

IODAX licenses external assets and develops them in collaboration with the licensors until they become high-potential pharmaceutical products. The number of assets is limited (maximum of 6). IODAX covers the development costs and provides dedicated project management after a thorough assessment of the scientific and commercial prospects. In this model, investors can benefit disproportionately from the founders’ scientific and industrial expertise.

Our Team

Unique radiopharmaceutical expertise, thought leadership, and track record

As trailblazers of the industry, the founders team has been centrally involved in all aspects of radiopharmaceutical product development, production, licensing, regulatory approval and commercialisation. A longstanding experience in the radiopharmaceutical industry, combined with an advanced scientific understanding, ensures a unique positioning of IODAX in the field.

Dr. Andreas Kluge – Chief Medical Officer

  • Physician, Founder and first GM1) of ABX advanced biochemical compounds, the leading manufacturer of radioprecursors (1996)
  • Founder and GM of ABX-CRO advanced pharmaceutical services,
    the globally first integrated radiopharmaceutical CRO (2002)
  • Co-founder and first CMO of TELIX Pharmaceuticals (market cap. > € 4.5 bn), the globally first fully integrated cash-flow positive radio-pharmaceuticals company focusing on radio-biopharmaceuticals (radioADC, 2017)
  • More than 25 years of dedicated radiopharmaceutical research, ranging from immunology, radiobiology, neuroimaging to oncology

1) General Manager

Matthias Untisz – Chief Financial Officer

  • Economist (MBA), LL.M. (commercial law), Founder and GM of the Business Consultancy firm Untisz & Coll. (2002), focusing on start-up management, financing and productification.
  • Associate lecturer of business economics, tax sciences, and entrepreneurship at the Brandenburg Technical University (BTU)
  • Interinstitutional Research Coordinator at the BTU (Brandenburg Technical University)
  • Deputy head of a Tax Consultancy firm (2006 – 2012)
  • More than 20 years of comprehensive hands-on business management experience covering all aspects of the company life-cycle (start-up, financing, growth & crisis management, restructuring) for multiple consultancy clients

Prof. Dr. Samuel Samnick – Chief Scientific Officer

  • Accomplished Radiochemist, Radiopharmacist & preclinical Experimentator, advanced several drugs (diagnostics and therapeutics) into clinical development in academic settings, out-licensed several compounds to the pharmaceutical industry
  • Professor of Experimental Nuclear Medicine and Radiopharmacy, Qualified Person & Director of PET center and Radiopharmacy at the University Hospital Würzburg (UKW)
  • Leading expert of halogen radiochemistry (18F, 123I, 124I, 131I and 211At), global pioneer of small molecule labelling with 211At
  • Chemical Process Engineer, experienced in large scale manufacturing and automation
  • More than 25 years of dedicated radiopharmaceutical research and (pre)clinical validations

Andreas Fintelmann – Chairman of the Board

  • Lawyer, founding Sales Director at ABX Advanced Biochemical Compounds, growing revenue from € 100k to over € 100m annually
  • Built personal and business relationships with > 250 world-leading radiopharmaceutical research institutions and inventors
  • In-licensed radiopharmaceutical blockbusters, including PSMA-617 (Pluvicto®, Novartis), which generated around € 1.0bn in revenues in 2023
  • As GM of PINAX Pharma, a radiogenerics manufacturer, he obtained EU marketing authorizations from EMA, and established a pharmaceutical manufacturing and wholesaler QA system
  • 25 years of radiopharmaceutical manufacturing & commercialization

Team Track Record

Unique positioning

in global theranostics community
> 300 scientific, medical & commercial points of contact

> 50 years

Cumulative experience in radiopharma development &
commercialisation

8 pharmaceuticals

successfully developed, approved & commercialized

€ 1.0bn

current turn-over of prior start-ups of founders